John Quisel
Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup
Until a few years ago, GlyT1, a glycine transporter, seemed like a promising target for an add-on therapy to treat negative symptoms of schizophrenia. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
